Investment bank Leerink Partners announced the initiation of research coverage on biotechnology company AgomAb Therapeutics (AGMB), assigning an "Outperform" rating.

老虎证券2026/03/03 12:00

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The institution has set a target stock price of $36 for the company, demonstrating a positive outlook on its future growth potential. This coverage marks an increased market focus on AgomAb Therapeutics' R&D pipeline. Leerink Partners' optimistic rating is based on an in-depth assessment of the company's core technology and business prospects.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Investment bank Leerink Partners announced the initiation of research coverage on biotechnology company AgomAb Therapeutics (AGMB), assigning an "Outperform" rating.

You may also like

Crypto prices